This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wallace, R. J.
Right arrow Articles by Wilson, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wallace, R. J., Jr.
Right arrow Articles by Wilson, R. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2001, p. 764-767, Vol. 45, No. 3
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.3.764-767.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Activities of Linezolid against Rapidly Growing Mycobacteria

R. J. Wallace Jr.,* B. A. Brown-Elliott, S. C. Ward, C. J. Crist, L. B. Mann, and R. W. Wilson

Department of Microbiology, University of Texas Health Center, Tyler, Texas

Received 5 September 2000/Returned for modification 8 November 2000/Accepted 4 December 2000

Linezolid is an oxazolidinone available as an oral drug which has activity against most gram-positive bacteria. However, few species of the genus Mycobacterium have been studied. We tested 249 clinical isolates and 10 reference strains of rapidly growing mycobacteria for susceptibility to linezolid by broth microdilution. Clinical species included the Mycobacterium fortuitum group (n = 74), M. abscessus (n = 98), M. chelonae (n = 50), M. mucogenicum (n = 10), and M. fortuitum third biovariant complex (10). The modal MIC for M. mucogenicum was 1.0 µg/ml, and the MIC at which 90% of the isolates tested are inhibited (MIC90) was 4 µg/ml; the modal MIC for the M. fortuitum group was 4 µg/ml, and the MIC90 was 16 µg/ml; the modal MIC for the M. fortuitum third biovariant complex was 4 µg/ml, and the MIC90 was 8 µg/ml; the modal MIC for M. chelonae was 8 µg/ml, and the MIC90 was 16 µg/ml; and the modal MIC for M. abscessus was 32 µg/ml, and the MIC90 was 64 µg/ml. Based on peak levels of linezolid in serum of 15 to 20 µg/ml, we propose the following broth MIC breakpoints for these species: susceptible, <=  8 µg/ml; moderately susceptible, 16 µg/ml; and resistant, >= 32 µg/ml). These studies demonstrate the excellent potential of linezolid for therapy of rapidly growing mycobacteria.

* Corresponding author. Mailing address: The University of Texas Health Center, Department of Microbiology, 11937 U.S. Hwy. 271, Tyler, TX 75708. Phone: (903) 877-7680. Fax: (903) 877-7652. E-mail: Joanne.Woodring{at}uthct.edu.

Antimicrobial Agents and Chemotherapy, March 2001, p. 764-767, Vol. 45, No. 3
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.3.764-767.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Jeon, K., Kwon, O J., Lee, N. Y., Kim, B.-J., Kook, Y.-H., Lee, S.-H., Park, Y. K., Kim, C. K., Koh, W.-J. (2009). Antibiotic Treatment of Mycobacterium abscessus Lung Disease: A Retrospective Analysis of 65 Patients. Am. J. Respir. Crit. Care Med. 180: 896-902 [Abstract] [Full Text]  
  • Fernandez-Roblas, R., Martin-de-Hijas, N. Z., Fernandez-Martinez, A. I., Garcia-Almeida, D., Gadea, I., Esteban, J. (2008). In Vitro Activities of Tigecycline and 10 Other Antimicrobials against Nonpigmented Rapidly Growing Mycobacteria. Antimicrob. Agents Chemother. 52: 4184-4186 [Abstract] [Full Text]  
  • Vera-Cabrera, L., Brown-Elliott, B. A., Wallace, R. J. Jr., Ocampo-Candiani, J., Welsh, O., Choi, S. H., Molina-Torres, C. A. (2006). In Vitro Activities of the Novel Oxazolidinones DA-7867 and DA-7157 against Rapidly and Slowly Growing Mycobacteria. Antimicrob. Agents Chemother. 50: 4027-4029 [Abstract] [Full Text]  
  • Ji, B., Lefrancois, S., Robert, J., Chauffour, A., Truffot, C., Jarlier, V. (2006). In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans.. Antimicrob. Agents Chemother. 50: 1921-1926 [Abstract] [Full Text]  
  • Wallace, R. J. Jr., Brown-Elliott, B. A., Brown, J., Steigerwalt, A. G., Hall, L., Woods, G., Cloud, J., Mann, L., Wilson, R., Crist, C., Jost, K. C. Jr., Byrer, D. E., Tang, J., Cooper, J., Stamenova, E., Campbell, B., Wolfe, J., Turenne, C. (2005). Polyphasic Characterization Reveals that the Human Pathogen Mycobacterium peregrinum Type II Belongs to the Bovine Pathogen Species Mycobacterium senegalense. J. Clin. Microbiol. 43: 5925-5935 [Abstract] [Full Text]  
  • Fortun, J., Martin-Davila, P., Navas, E., Perez-Elias, M. J., Cobo, J., Tato, M., De la Pedrosa, E. G.-G., Gomez-Mampaso, E., Moreno, S. (2005). Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 56: 180-185 [Abstract] [Full Text]  
  • Guna, R., Munoz, C., Dominguez, V., Garcia-Garcia, A., Galvez, J., de Julian-Ortiz, J.-V., Borras, R. (2005). In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J Antimicrob Chemother 55: 950-953 [Abstract] [Full Text]  
  • Turenne, C. Y., Thibert, L., Williams, K., Burdz, T. V., Cook, V. J., Wolfe, J. N., Cockcroft, D. W., Kabani, A. (2004). Mycobacterium saskatchewanense sp. nov., a novel slowly growing scotochromogenic species from human clinical isolates related to Mycobacterium interjectum and Accuprobe-positive for Mycobacterium avium complex. Int. J. Syst. Evol. Microbiol. 54: 659-667 [Abstract] [Full Text]  
  • Yang, S.-C., Hsueh, P.-R., Lai, H.-C., Teng, L.-J., Huang, L.-M., Chen, J.-M., Wang, S.-K., Shie, D.-C., Ho, S.-W., Luh, K.-T. (2003). High Prevalence of Antimicrobial Resistance in Rapidly Growing Mycobacteria in Taiwan. Antimicrob. Agents Chemother. 47: 1958-1962 [Abstract] [Full Text]  
  • Brown-Elliott, B. A., Crist, C. J., Mann, L. B., Wilson, R. W., Wallace, R. J. Jr. (2003). In Vitro Activity of Linezolid against Slowly Growing Nontuberculous Mycobacteria. Antimicrob. Agents Chemother. 47: 1736-1738 [Abstract] [Full Text]  
  • Moellering, R. C. Jr. (2003). Linezolid: The First Oxazolidinone Antimicrobial. ANN INTERN MED 138: 135-142 [Abstract] [Full Text]  
  • Brown-Elliott, B. A., Wallace, R. J. Jr. (2002). Clinical and Taxonomic Status of Pathogenic Nonpigmented or Late-Pigmenting Rapidly Growing Mycobacteria. Clin. Microbiol. Rev. 15: 716-746 [Abstract] [Full Text]  
  • Brown-Elliott, B. A., Wallace, R. J. Jr., Crist, C. J., Mann, L., Wilson, R. W. (2002). Comparison of In Vitro Activities of Gatifloxacin and Ciprofloxacin against Four Taxa of Rapidly Growing Mycobacteria. Antimicrob. Agents Chemother. 46: 3283-3285 [Abstract] [Full Text]  
  • Wallace, R. J. Jr., Brown-Elliott, B. A., Hall, L., Roberts, G., Wilson, R. W., Mann, L. B., Crist, C. J., Chiu, S. H., Dunlap, R., Garcia, M. J., Bagwell, J. T., Jost, K. C. Jr. (2002). Clinical and Laboratory Features of Mycobacterium mageritense. J. Clin. Microbiol. 40: 2930-2935 [Abstract] [Full Text]  
  • Conte, J. E. Jr., Golden, J. A., Kipps, J., Zurlinden, E. (2002). Intrapulmonary Pharmacokinetics of Linezolid. Antimicrob. Agents Chemother. 46: 1475-1480 [Abstract] [Full Text]  
  • Braback, M., Riesbeck, K., Forsgren, A. (2002). Susceptibilities of Mycobacteriummarinum to Gatifloxacin, Gemifloxacin, Levofloxacin, Linezolid, Moxifloxacin, Telithromycin, and Quinupristin-Dalfopristin (Synercid) Compared to Its Susceptibilities to Reference Macrolides and Quinolones. Antimicrob. Agents Chemother. 46: 1114-1116 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»